Please login to the form below

Not currently logged in

Takeda opens new UK office in High Wycombe

Hopes move to larger premises will help expand business
Takeda UK office

The opening included the traditional Japanese Kagamiwari ceremony where a barrel of saki is broken open with a wooden mallet 

The UK subsidiary of Takeda, Japan's leading pharma company, has opened a new office branch in High Wycombe, England.

The firm hopes the move to larger premises will allow the company to expand the business by creating an "inspiring work environment" and providing space for the 79-strong team to grow.

The official opening took place this week and included a presentation from Andy Hook, UK Trade & Investment Life Sciences Organisation. The event was also attended by Dennis Lauth, area head of northern Europe for Takeda Pharma International.

Yasuhiro Fukutomi, UK managing director, said: “The move reflects Takeda's commitment to build on our successful business within the UK. Takeda has a strong heritage and medicines within primary care, and we will continue to develop in these areas and introduce new medicines within the specialty arena.

“I am quite sure that our new premises will be conducive to enhanced collaboration, agility and innovation at the highest level within the organisation."

Article by
Kirstie Pickering

10th October 2014

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...